Michael Shetzline - Mar 8, 2023 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
CMO,SVP,Head-Res&Drug
Signature
/s/ Brian Tessler, Attorney-in-Fact
Stock symbol
IRWD
Transactions as of
Mar 8, 2023
Transactions value $
$0
Form type
4
Date filed
3/10/2023, 04:13 PM
Previous filing
Mar 1, 2023
Next filing
May 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Award $0 +69.9K +26.71% $0.00 331K Mar 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRWD Performance-based Restricted Stock Units Award $0 +34.9K $0.00 34.9K Mar 8, 2023 Class A Common Stock 34.9K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
F2 Each performance-based restricted stock unit (PSU) represents a contingent right to receive shares of the Issuer's Class A Common Stock upon vesting such award. The PSUs vest upon the Issuer's Class A Common Stock achieving a specified price per share.